Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Xilio Therapeutics, Inc..
Xilio Therapeutics, Inc. is a company.
Key people at Xilio Therapeutics, Inc..
Xilio Therapeutics, Inc. (XLO) is a clinical-stage biotechnology company developing tumor-selective immunotherapies to treat cancer by activating potent immune responses precisely within tumors, minimizing systemic side effects.[1][2][3] It serves cancer patients across multiple tumor types with a pipeline of masked biologics, including bispecifics and T cell engagers targeting IL-2, CTLA4, and IL-12 pathways, addressing the core problem of toxicity that limits existing immuno-oncology (IO) therapies like IL-2 and anti-CTLA4.[2][3][4][6] The company's proprietary platform uses tumor-activated masking cleaved by matrix metalloproteases (MMPs) in the tumor microenvironment (TME), enabling higher efficacy and broader patient access; key programs like XTX202 (IL-2), XTX101 (anti-CTLA4), and XTX301 (IL-12) are in Phase 1/2 trials, with partnerships like AbbVie signaling growth momentum.[3][7][8]
Founded in 2016 and headquartered in Waltham, Massachusetts, Xilio Therapeutics emerged from the vision to create "Ex Nihilo"—from nothing—transformative cancer treatments by harnessing IO therapies selectively in tumors.[1][4][6] While specific founders are not detailed in available sources, the company quickly built expertise around its proprietary tumor-activated platform, validated in preclinical models showing superior therapeutic indices for cytokines like IL-2.[3][4] Early traction included raising $95 million in Series C financing in 2021 from investors like Bain Capital and Rock Springs Capital to advance XTX202 and XTX101 into clinical stages, marking pivotal momentum in IO innovation.[6]
Xilio rides the IO wave, where therapies like checkpoint inhibitors and cytokines show curative potential but are hampered by dose-limiting toxicities from systemic exposure.[2][3] Timing aligns with advances in tumor microenvironment targeting and biologics engineering, amplified by market forces like rising cancer incidence and demand for precision medicine. Its platform influences the ecosystem by enabling "ultra-potent" versions of validated mechanisms (e.g., masked IL-2 variants), potentially expanding treatable patients and partnering with big pharma like AbbVie to accelerate IO evolution.[4][6][7]
Xilio is poised for milestone readouts from Phase 1/2 trials of lead assets like XTX202 and XTX101, with potential data in 2026 driving partnerships or approvals amid IO's shift toward localized activation.[3][8] Trends like bispecific TCEs and cytokine engineering will shape its path, possibly evolving it into a leader in TME-selective therapies if toxicity hurdles are cleared. Returning to its "Ex Nihilo" roots, Xilio could redefine cancer care by unleashing IO's full power tumor-by-tumor.[1][2]
Key people at Xilio Therapeutics, Inc..
